Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - GT Biopharma, Inc. | Financial_Report.xls |
| EX-31.1 - EXHIBIT 31.1 - GT Biopharma, Inc. | ex311.htm |
| EX-10.21 - FORM OF SERIES A WARRANT ISSUED WITH 8% CONVERTIBLE DEBENTURE - GT Biopharma, Inc. | ex1021seriesa.htm |
| EX-10.20 - FORM OF 8% CONVERTIBLE DEBENTURE - GT Biopharma, Inc. | ex1020debenture.htm |
| EX-10.23 - STANDSTILL AND FORBEARANCE AGREEMENT DATED AS OF MAY 15, 2012 - GT Biopharma, Inc. | ex1023standstill.htm |
| 10-Q - OXIS 10-Q MARCH 31, 2012 - GT Biopharma, Inc. | oxis10qq12012.htm |
| EX-10.22 - FORM OF SERIES B WARRANT ISSUED WITH 8% CONVERTIBLE DEBENTURE - GT Biopharma, Inc. | ex1022seriesb.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of OXIS International, Inc. (the “Company”) for the quarter ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David Saloff, Chief Executive Officer and Acting Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: May 21, 2012
|
By: /s/ David Saloff
|
|
David Saloff
|
|
|
Chief Executive Officer and Acting Chief Financial Officer
|
This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.